<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164253</url>
  </required_header>
  <id_info>
    <org_study_id>2012_69</org_study_id>
    <secondary_id>2013-001228-21</secondary_id>
    <nct_id>NCT02164253</nct_id>
  </id_info>
  <brief_title>Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients</brief_title>
  <acronym>SAFEFAIRALS</acronym>
  <official_title>Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FAIR-ALS study is to investigate the safety and efficacy of a scavenger treatment of iron
      deferiprone, which would reduce the brain iron to limit the development of amyotrophic
      lateral sclerosis.

      It has been shown an excess of iron in the central nervous system carrying a sporadic ALS
      patients. Iron overload associated with a loss of motor neurons may explain the signs of the
      disease (atrophy).

      The investigators discuss the hypothesis that reducing excess iron, the investigators can
      reduce the loss of neurons and thus the progression of signs of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the end of the study, it will propose to continue the usual quarterly patient follow up,
      as recommended by the French ALS centers.

      Deferiprone can be administered as part of a compassionate use, for patients who want it and
      who do not have hypoxemia.

      We therefore plan a treatment period compassionate relatively short and less than 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of Amyotrophic Lateral Sclerosis Functional Rating Scale</measure>
    <time_frame>V3, V6, V9, V12, V15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the progression of ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale ) score for 3 months without treatment (V0 to V3) in the period of the first three months under treatment (V3 to V6).</measure>
    <time_frame>SCREENING, V0, V3, V6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who become non-self-sufficient after 12 months with the appearance of a sub scores ALSFRS-R less than or equal to 2 on swallowing, cut food using utensils or walk.</measure>
    <time_frame>SCREENING, V0, V3, V6, V9, V12, V15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with anemia at 12 months defined by a hemoglobin / dL Hb &lt;12 g</measure>
    <time_frame>V3, V6, V9, V12, V15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious and non-serious adverse events</measure>
    <time_frame>SCREENING, V0, V3, V6, V9, V12, V15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of respiratory vital capacity tests</measure>
    <time_frame>SCREENING, V0, V3, V6, V9, V12, V15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Values of R2 * in MRI</measure>
    <time_frame>V3, V6, V19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress markers analyzed blindly in blood and cerebrospinal fluid</measure>
    <time_frame>V3, V9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No alteration of energy metabolism in aerobic and anaerobic blood and cerebrospinal fluid</measure>
    <time_frame>V3, V9</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>ALS (Amyotrophic Lateral Sclerosis)</condition>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>Deferiprone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferiprone, 25 to 30 mg/kg per day, oral use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone</intervention_name>
    <description>30 mg/kg per day, oral use</description>
    <arm_group_label>Deferiprone</arm_group_label>
    <other_name>Ferriprox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Amyotrophic lateral sclerosis defined in accordance to the El Escorial criteria
             (possible, probable or defined)

          -  18 to 85 years old patient, male or female

          -  Patient with social security cover

        Exclusion Criteria:

          -  Achieved respiratory defined by a FVC &lt;70%

          -  Evolution of more than 24 months

          -  Demented subject

          -  Severe malnutrition

          -  Patients with treatment potentially at risk of agranulocytosis and neutropenia

          -  Patients with a history of agranulocytosis or iatrogenic under haematological disease

          -  Incapable of giving consent

          -  Indication against MRI

          -  Indication against lumbar puncture

          -  Patient refused lumbar puncture

          -  Hypersensitivity to iron chelators

          -  Concomitant treatment with antacids containing aluminum

          -  Presence of another serious illness to life-threatening or disabling cons to the use
             of the treatment mixture of oxygen and nitrous oxide equally
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Moreau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994 Mar 3;330(9):585-91.</citation>
    <PMID>8302340</PMID>
  </reference>
  <reference>
    <citation>Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007 Jul 1;110(1):401-8. Epub 2007 Mar 22.</citation>
    <PMID>17379741</PMID>
  </reference>
  <reference>
    <citation>Danzeisen R, Achsel T, Bederke U, Cozzolino M, Crosio C, Ferri A, Frenzel M, Gralla EB, Huber L, Ludolph A, Nencini M, Rotilio G, Valentine JS, Carrì MT. Superoxide dismutase 1 modulates expression of transferrin receptor. J Biol Inorg Chem. 2006 Jun;11(4):489-98. Epub 2006 Apr 26.</citation>
    <PMID>16680451</PMID>
  </reference>
  <reference>
    <citation>Felice KJ. A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve. 1997 Feb;20(2):179-85.</citation>
    <PMID>9040656</PMID>
  </reference>
  <reference>
    <citation>Goodall EF, Greenway MJ, van Marion I, Carroll CB, Hardiman O, Morrison KE. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology. 2005 Sep 27;65(6):934-7.</citation>
    <PMID>16186539</PMID>
  </reference>
  <reference>
    <citation>Kwiatkowski A, Ryckewaert G, Jissendi Tchofo P, Moreau C, Vuillaume I, Chinnery PF, Destée A, Defebvre L, Devos D. Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat Disord. 2012 Jan;18(1):110-2. doi: 10.1016/j.parkreldis.2011.06.024. Epub 2011 Aug 6.</citation>
    <PMID>21821461</PMID>
  </reference>
  <reference>
    <citation>Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci. 1998 May 1;18(9):3241-50.</citation>
    <PMID>9547233</PMID>
  </reference>
  <reference>
    <citation>Langkammer C, Enzinger C, Quasthoff S, Grafenauer P, Soellinger M, Fazekas F, Ropele S. Mapping of iron deposition in conjunction with assessment of nerve fiber tract integrity in amyotrophic lateral sclerosis. J Magn Reson Imaging. 2010 Jun;31(6):1339-45. doi: 10.1002/jmri.22185.</citation>
    <PMID>20512885</PMID>
  </reference>
  <reference>
    <citation>Lin J, Diamanduros A, Chowdhury SA, Scelsa S, Latov N, Sadiq SA. Specific electron transport chain abnormalities in amyotrophic lateral sclerosis. J Neurol. 2009 May;256(5):774-82. doi: 10.1007/s00415-009-5015-8. Epub 2009 Feb 25.</citation>
    <PMID>19240958</PMID>
  </reference>
  <reference>
    <citation>Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann H, Sauer D, Silani V, Strong M, Swash M, Vernotica E; TCH346 Study Group. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007 Aug 21;69(8):776-84.</citation>
    <PMID>17709710</PMID>
  </reference>
  <reference>
    <citation>Moreau C, Gosset P, Kluza J, Brunaud-Danel V, Lassalle P, Marchetti P, Defebvre L, Destée A, Devos D. Deregulation of the hypoxia inducible factor-1α pathway in monocytes from sporadic amyotrophic lateral sclerosis patients. Neuroscience. 2011 Jan 13;172:110-7. doi: 10.1016/j.neuroscience.2010.10.040. Epub 2010 Oct 25.</citation>
    <PMID>20977930</PMID>
  </reference>
  <reference>
    <citation>Moreau C, Devos D, Gosset P, Brunaud-Danel V, Tonnel AB, Lassalle P, Defebvre L, Destée A. [Mechanisms of deregulated response to hypoxia in sporadic amyotrophic lateral sclerosis: a clinical study]. Rev Neurol (Paris). 2010 Mar;166(3):279-83. doi: 10.1016/j.neurol.2009.05.018. Epub 2009 Aug 5. Review. French.</citation>
    <PMID>19660777</PMID>
  </reference>
  <reference>
    <citation>Moreau C, Gosset P, Brunaud-Danel V, Lassalle P, Degonne B, Destee A, Defebvre L, Devos D. CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients. Amyotroph Lateral Scler. 2009 Jun;10(3):175-81. doi: 10.1080/17482960802651725.</citation>
    <PMID>19177252</PMID>
  </reference>
  <reference>
    <citation>Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destée A, Tonnel AB, Lassalle P, Just N. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):255-7.</citation>
    <PMID>16421133</PMID>
  </reference>
  <reference>
    <citation>Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destée A, Tonnel AB, Lassalle P, Just N. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology. 2005 Dec 27;65(12):1958-60.</citation>
    <PMID>16380619</PMID>
  </reference>
  <reference>
    <citation>Noto Y, Misawa S, Kanai K, Shibuya K, Isose S, Nasu S, Sekiguchi Y, Fujimaki Y, Nakagawa M, Kuwabara S. Awaji ALS criteria increase the diagnostic sensitivity in patients with bulbar onset. Clin Neurophysiol. 2012 Feb;123(2):382-5. doi: 10.1016/j.clinph.2011.05.030. Epub 2011 Jul 20.</citation>
    <PMID>21764635</PMID>
  </reference>
  <reference>
    <citation>Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011 Jul;70(1):79-83. doi: 10.1002/ana.22380. Epub 2011 Mar 17.</citation>
    <PMID>21437935</PMID>
  </reference>
  <reference>
    <citation>Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D; Northeast ALS Consortium. Revised statistical motor unit number estimation in the Celecoxib/ALS trial. Muscle Nerve. 2007 Feb;35(2):228-34.</citation>
    <PMID>17058270</PMID>
  </reference>
  <reference>
    <citation>Shefner JM, Watson ML, Simionescu L, Caress JB, Burns TM, Maragakis NJ, Benatar M, David WS, Sharma KR, Rutkove SB. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology. 2011 Jul 19;77(3):235-41. doi: 10.1212/WNL.0b013e318225aabf. Epub 2011 Jun 15.</citation>
    <PMID>21676915</PMID>
  </reference>
  <reference>
    <citation>Yuen EC, Olney RK. Longitudinal study of fiber density and motor unit number estimate in patients with amyotrophic lateral sclerosis. Neurology. 1997 Aug;49(2):573-8.</citation>
    <PMID>9270599</PMID>
  </reference>
  <reference>
    <citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70.</citation>
    <PMID>6880820</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

